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Summaeo The expression and prognostic significance of the c-erbB-2 oncogene product was studied in 55
cases of childhood medulloblastoma. Forty-six of the 55 tumours (83.6%) expressed the c-erbB-2 product. The
percentage of tumour cells expressing the c-erbB-2 product proved to be a significant indicator of patient
outcome when analysed as both a categorical and a continuous vanrable. As a categorical variable, patients
with more than 50% positive tumour cells had a significantly worse survival, with only 10% alive at 10 years
Vs 48% for those with less than 50% positive tumour cells (log rank P = 0.0049). To demonstrate that this
observed prognostic significance was both independent and not a result of 'data-driven' categorisation. it was
also entered into the Cox model as a continuous variable. Prognostic significance was retained with
P= 0.038-
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Medulloblastoma is one of the commonest malignant
tumours of the posterior fossa in children. Current surgical,
and radiotherapy techniques achieve cure in between 50%
and 60% of affected children (Tait et al., 1990). However,
because the prognostic factors for this disease are not well
established it has proved difficult to identify those patients
who will ultimately respond to current treatment protocols.
This reduces the efficient use of existing treatment regimens
and the development of new therapies for non-responders.
Various clinical disease features such as patient age (Jenkin
et al.. 1990; Zerbini et al., 1993), sex (Bloom et al., 1969;
Berry et al., 1981; Zerbini et al., 1993) and degree of surgical
resection (Jenkin et al., 1990; Zerbini et al., 1993) have
proved unreliable in predicting disease outcome. Only the
presence of metastases at diagnosis (Allen and Epstein, 1982;
Kopelson et al., 1983; Caputy et al., 1987; Jenkin et al., 1990;
Zerbini et al., 1993) and use of posterior fossa radiotherapy
dosage <50Gy (Berry et al., 1981; Kopelson et al., 1983;
Zerbini et al.. 1993) appear constistently to indicate a poor
outcome.
In recent years biological disease markers have improved
the accuracy of prognostic prediction for many tumours.
Moreover, the development of immunohistochemical techni-
ques has permitted their rapid and widespread investigation.
One such group of markers are oncogenes and their protein
products. In the present study we investigated the expression
and prognostic significance of the c-erbB-2 oncogene product
in childhood medulloblastoma. This oncogene has previously
been extensively studied in breast cancer, demonstrating a
significant relationship between overexpression of its product
by tumour cells and poor prognosis (Slamon et al., 1989;
Gullick et al., 1991; Lovekin et al., 1991; Winstanley et al.,
1991). The rodent counterpart of the c-erbB-2 gene, termed
c-neu, was first identified in transplacentally induced rat
neuroectodermal tumours of the central nervous system, pro-
viding evidence for the involvement of this oncogene in the
development of central neuroectodermal tumours (Schecter et
al., 1984). In addition, the commonest chromosomal abnor-
mality in medulloblastoma is an iso-chromosome of the long
arm of chromosome 17 (iso 17q) (Bigner et al., 1988). The
c-erbB-2 gene is located on the long arm of chromosome 17
(Fukushige et al., 1986) and so is potentially involved in the
abnormality.
.Materias and methods
Sixty-five children less than 15 years of age with medulloblas-
toma were notified to the Northern Region Young People's
Malignant Disease Registry between 1968 and 1988 (Craft et
al.. 1987). Four of these patients died in the post-operative
period from surgical complications. Tumour material was not
available for six patients. The tumours from the remaining 55
patients were studied. The age at diagnosis ranged from I
month to 14 years with a mean of 6.3 years. Thirty-seven
patients were male and 18 female. Fifty-three of the patients
received a combination of surgery (total, partial or biopsy
resection) with post-operative posterior fossa and cranio-
spinal radiotherapy. Two patients were subjected to surgery
alone. In addition, 24 patients received post-operative chemo-
therapy. In all but two this included vincristine with or
without CCNU. The remaining patients received cyclophos-
phamide and 5-fluorouracil or 8 in 1 therapy (vincristine,
cyclophosphamide, methylprednisolone, CCNU, procarba-
zine, cisplatin, hydroxyurea and cytosine).
The vast majority of patients had no accurate information
regarding disease stage at diagnosis. This lack of data
reflected both a deficiency in sensitive and routinely available
imaging techniques over the period 1968-88 and the absence
of a uniformly accepted method of disease staging. Therefore
disease stage could not be analysed as a prognostic factor in
this study.
All experimental procedures were performed using 10%
formalin-fixed paraffin embedded tumour material obtained
from the patients at operation. For each case, all available
tumour blocks were collected for study from the Newcastle
and Middlesbrough Neuropathology archives and diagnosis
was confirmed by RHP.
The monoclonal antibody NCL-CB1 1, generated to a syn-
thetic peptide sequence of predicted antigenicity near the
C-terminus of the protein (Corbett et al., 1990), was used to
detect the c-erbB-2 oncogene product in tumour sections by
the avidin-biotin-peroxidase complex technique (Hsu et al.,
1981). Five micrometre parafiin-embedded sections were cut
and mounted on silanised glass slides. These were then de-
waxed in xylene and rehydrated in serial alcohol solutions.
Endogenous preroxidase activity was blocked by incubation
in hydrogen peroxide/methanol solution followed by block-
ade of non-specific binding sites using 1.5% normal horse
serum in Tris-buffered saline (TBS). Sections were then
incubated for 16 h at 4°C in a solution of NCL CB mono-
clonal antibody (Novocastra) made up to a strength of 1:40
using 1.5% normal horse serum in TBS. Following washing
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in TBS, binding of the primary antibody was demonstrated
with a standard avidin-biotin-peroxidase complex technique
(Vectastain). This method employs a biotinylated sheep anti-
mouse antibody solution followed by a colorant reaction of
0.5% diaminobenzidine and hydrogen peroxide in TBS. Sec-
tions were then counteredstained with haematoxylin.
Four controls were employed. As negative controls either
primary or secondary antibodies were substituted for normal
serum in the staining protocol. In addition, an antigen
absorption control was performed using primary antibody
first incubated with its antigen. Finally breast carcinoma
tissue known to express the c-erbB-2 protein was employed
as a positive control.
All analyses were performed blind on separate occasions
by RHP and RJG. Discrepancies in staining analysis occur-
red in seven cases. These were re-examined on a multiheaded
microscope and consensus reached. Staining was scored for
three parameters: pattern of section staining, intensity of
tumour cell stain and estimated percentage of section stain-
ing.
Patient survival was assessed using Kaplan-Meier survival
curves and the log-rank test (Peto and Pike, 1973). Initial
analysis was performed to compare the prognosis of those
patients receiving chemotherapy, surgery and radiotherpy
with those undergoing surgery and radiotherapy alone. No
significant survival difference was observed between these two
groups (P = 0.80). Similar analysis of patient age, sex,
posterior fossa radiotherapy dose greater or less than 50 Gy
and degree ofsurgical resection (total vs partial resection) for
the study population also failed to reveal any prognostic
signifi of these variables (P = 0.99, 0.99, 0.23 and 0.50
respectively). The population was therefore analysed as a
single group in all subsequent analysis ofc-erbB-2 expression
and survival.
Following univariate analysis the continuous variable 'per-
centage of positive tumour cells' was analysed in the Cox
regression model with other variables including age, sex,
posterior radiotherapy dose and degree of surgical resection
received (Cox, 1972). This allowed the further assessment of
its independent prognostic significance without the risk of
'data-driven' categorisation.
Resdts
Forty-six of the 55 tumours (83.6%) expressed the c-rbB-2
product (Figure 1). The sparse cytoplasmic rim characteristic
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tumour cell c-erbB-2 product expression. Scale bar =20 pm.of medulloblastoma cells rendered difficult the distinction
between cytoplamic and membrane-associated c-erbB-2
immunoreactivity. The rmaining nine (16.4%) showed no
evidence of reactivity. All control sections were negative
(Figure 2).
Cytoplamic c-erbB-2 positivity was also seen in several
normal cell types, including vascular endothelium, smooth
muscle, choroid plexus epithelial cells. neurones and Purkinje
cells. Staining of Purkinje cells was especally pronounced,
often producting intense coarse granular cytoplasmic stain-
ing.
At low power the majority of cases revealed a hetero-
geneous distribution of positive tumour cells throughout the
section. However, nine (19.6%) positive tumours demon-
strated a focal pattern of tumour cell positivity (Figure 3).
Such cases were characterised by islands of between 15 and
more than 100 positive tumour cells, surrounded by large
areas of faintly or non-staining tumour tissue. The distribu-
tion of foci appeared to be random, with no relationship to
tumour vasularity or site within the tumour.
On a semiquantitative 1-4 scale, positive sections were
scored as either 0, +, + + or + + + based on the most
frequent intensity pattern observed within tumour sections.
Twenty-two (47.8%) positive tumours had a predominance
of intensely staining cells (+ + +), while moderate positivity
(+ +) was seen in 18 (39.1%) and faint positivity (+) in the
remaining six (13.1%).
The estimated percentage of tumour calls demonstrating
c-erbB-2 product immunoreactiity within sections ranged
from less than 10% to more than 80%. Twenty-thre cases
(50%) had an estimated section positivity of more than 50%
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(Figure 4). The rmiaining sections expressed the c-erbB-2
product in fewer than 50% of cells (Figure 5).
The survival curves for the three staining variables and
their respective log-rank- test scores are summarsd in
Figures 6-8. There was no significant difference in prognosis
between the three groups defined by the intensity of tumour
staining (log rank P= 0.46). T1h macroscopic pattern of
tumour cell c-erbB-2 product expression also appeared to
lack prognostic sig c in univariate analysis with vir-
tually identical survival rates of 30% and 31% respectively
for the two categories, focal and non-focal staining (log rank
P=0.75).
In contrast, the percentage of tumour cells expressing the
c-erbB-2 product proved to be a significnt indicator of
patient outcome when analysed as both a categorical and
continuous vanable. As a categorical variable patients were
divied into two groups: more or less than 50% tumour cells.
The survival curve for these two categories is shown in
Figure 8. Patients with more than 50% positive tumour cells
had a signntly worse survival, with only 10% alive at 10
years vs 48% for those with less than 50% positive tumour
cells (log rank P= 0.0049). To demonstrate that this observ-
ed prognostic signifi was independent and not a result
of 'data driven' categorisation, it was also entered into the
Cox model as a continuous variable with other variables.
These included age, sex, degree of surgical resection and
posterior fossa radiotherapy dose. Only c-erbB-2 oncogene
product expression retained prognostic signif with
P= 0.038.
Disde
This study has demonstrated tumour cell expression of the
c-erbB-2 oncogene product in a high proportion (83.6%) of
childhood medulloblastomas. In addition, it reveals a
significant relationship between the number of tumour cells
expressing this oncogene product and patient prognosis.
Patients whose tumours had c-erbB-2 immunoreactivity in
less than 50% of tumour cells had a significantly improved
10 year survival in both log-rank and Cox analyses when
compared with patients in whom more than 50% of tumour
cells were positive for c-erbB-2 product. No significant rela-
tionship between patient survival and either the intensity of
tumour cell staining or the distribution of positive cells was
found. This lack of prognostic signifi may relate to the
small size of our study population, and further analysis is
required before these two variables can be dismised as being
of no prognostic value.
The sparse rim of cytoplasm characteristic of primitive
neuroectodermal tumour (PNET) cells rendered it difficult to
attribute cell product immunostaining to membrane or cytop-
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lasm. The c-erbB-2 oncogene encodes a transmembrane
growth factor receptor. However, both membrane and cytop-
lasmic expression is a well-recognised feature of c-erbB-2
(Gullick et al., 1987; Corbett et al., 1990; Winstanley et al.,
1991) and other members of the receptor tyrosine kinase
family, including the epidermal growth factor receptor
(EGFR) (Gullick et al., 1991) and the more recently des-
cribed c-erbB-3 receptor (Poller et al., 1992). Although cytop-
lasic immunoreactivity has been proposed to represEnt
post-translational processing of receptor protein before mem-
brane insertion, this remains controversial (Poller et at.,
1992).
In addition to tumour cell expresson, specific nnmuno-
staining of several normal tissues was also demonstrated.
This included heterogeneous staining of neurones and Pur-
kinje cells, vascular endothelium and smooth muscle. Expres-
sion ofc-erbB-2 by these normal tisues has been described in
both human (Quirke et al., 1989) and rat (Kokai et al., 1987)
fetuses. However, expression by mature human nervous tis-
sue has not been consistently demonstrated (Natali et al.,
1990 Press et al., 1990). In recent years various mechanisms
have been proposed for the employment ofantibodies direct-
ed against the c-erbB-2 product in the treatment of tumours
expressing this protein. These include the enh nmt of
T-cell cytotoxicity (Shalaby et al., 1992), use as immuno-
toxins and cytotoxin targeting or immunotherapy (Tagliabue
et al., 1991). Cearly, before such techniques could be con-
sidered an in-depth understanding of the expression of c-
erbB-2 protein by normal tissues such as those described in
the present study would be required.
Finally, various hypotheses have been suggested to explain
the potential mechanism by which c-erbB-2 may initiate and
promote malignant transformation. As stated earler, the c-
erbB-2 oncogene encodes a tranembrane growth factor
receptor. Abnormalities in either the quality or quantity of
c-erbB-2 product expressed with or without interaction with
its native ligand may therefore lead to breakdown in the
control of normal mitogenic signal transduction (Bargmann
and Wienberg, 1988; Di Fiore et al., 1990). With regard to
ligand interactions, Marchionni et al. (1993) have recently
described a family ofpotential ligands for the c-erbB-2 recep-
tor collectively termed the neureguln. When exposed to
c-erbB-2-expressing cells, these proteins cause phosphoryla-
tion of the c-erbB-2 receptor and cell proliferation. Demons-
tration of neuregulin expression in the developing nervous
system has led to the proposal that paracrine and autocrine
procses involving c-erbB-2 recptor and ligand may play a
key role in the development of early central nervous system
tumours (Marchionni et al., 1993). At the receptor level
studies in human tumours have demonstrated overexpression
of an otherwise normal c-erbB-2 product, leading to uncon-
trolled mitogenic signalling. One process by which overex-
pression may be achieved is- oncogene amplification. This is
principally a feature of adenocarcinomas (Yokota et al.,
1986) and has been described in breast (Yokota et al., 1986;
Bg et al., 1988; Slamon et al., 1989), gastric (Fukushige et
al., 1986; Kameda et al., 1990), renal (Yokoto et al., 1986)
and colonic tumours (Guttman et al., 1989). To date there
have been no studies of the c-erbB-2 gene locus in medullo-
blastoma, and so it is unclar by what mechanism the
oncogene is activated. However, the normal proto-oncogene
c-erbB-2 maps to the long arm of chromsome 17 at q21
(Fukushige et al., 1986). The principal non-random chromo-
somal abnormality ofmedulloblastoma is an iso-chromosome
of the long arm chromosome 17, which can be present in
multiple copies (Bigner et al., 1988). This potentially results
in the presence of multiple copies of the c-erbB-2 oncogene
and hence a mechanisn by which the gene may be 'amplifi-
ed'. In the present study expression of the c-erbB-2 product
was observed in 83.6% of cases, however the iso 17q abnor-
mality is present in only 30-40% of medulloblastomas
.(Bigner et al., 1988; Griffin et al., 1988; Biegel et al., 1989;
Stewart et al., 1990). This chromosomal abnormality is there-
fore unlikely to be the only potential cause of c-erbB-2
overexpression in this malignancy.
This study has demonstrated the expression of c-erbB-2
oncogene product in a high proportion ofchildhood maulo-
blastomas. In addition, the percentage of tumour cells ex-
pressing the c-erbB-2 product is signifiantly and inde-
pendently related to patient prognosis. Further analysis of
c-erbB-2 oncogene in medulloblastoma and normal nervous
tissw is required to undentand fully its potential role in both
the pathogenesis of this malignancy and future
immunotherapy.
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